Clinical trial
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
NCT03786094
Study timeline
Study start (actual)2019-05-30Date precision: day
Registry last updated2023-11-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Breast Cancerunresolved
Locally Recurrent Breast Cancerunresolved
Interventions
EribulinDRUG · verified · RxNorm: eribulin
BalixafortideDRUG
Sponsors & collaborators
Spexis AGlead sponsor
Mapped research locations
MadridSpain3SeoulSouth Korea2TaipeiTaiwan2Kansas CityMissouri, United States2New YorkNew York, United States1Los AngelesCalifornia, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1BarcelonaSpain1LondonUnited Kingdom1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03786094 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.